These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28591025)

  • 1. Neurocognitive development in HIV-positive children is correlated with plasma viral loads in early childhood.
    Weber V; Radeloff D; Reimers B; Salzmann-Manrique E; Bader P; Schwabe D; Königs C
    Medicine (Baltimore); 2017 Jun; 96(23):e6867. PubMed ID: 28591025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor cognitive functioning of school-aged children in thailand with perinatally acquired HIV infection taking antiretroviral therapy.
    Puthanakit T; Aurpibul L; Louthrenoo O; Tapanya P; Nadsasarn R; Insee-ard S; Sirisanthana V
    AIDS Patient Care STDS; 2010 Mar; 24(3):141-6. PubMed ID: 20214481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between markers of vascular dysfunction and neurodevelopmental outcomes in perinatally HIV-infected youth.
    Kapetanovic S; Leister E; Nichols S; Miller T; Tassiopoulos K; Hazra R; Gelbard HA; Malee KM; Kammerer B; Mendez AJ; Williams PL;
    AIDS; 2010 Jun; 24(10):1481-91. PubMed ID: 20539091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice.
    Gondrie IPE; Bastiaans DET; Fraaij PLA; Driessen GJA; van der Knaap LC; Visser EG; van Jaarsveld P; de Groot R; Hartwig NG; Burger DM; van Rossum AMC
    Pediatr Infect Dis J; 2017 Oct; 36(10):976-980. PubMed ID: 28475554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
    Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
    J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
    Rojas Sánchez P; Prieto L; Jiménez De Ory S; Fernández Cooke E; Navarro ML; Ramos JT; Holguín Á;
    PLoS One; 2017; 12(3):e0173168. PubMed ID: 28350802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early viral suppression improves neurocognitive outcomes in HIV-infected children.
    Crowell CS; Huo Y; Tassiopoulos K; Malee KM; Yogev R; Hazra R; Rutstein RM; Nichols SL; Smith RA; Williams PL; Oleske J; Muller WJ;
    AIDS; 2015 Jan; 29(3):295-304. PubMed ID: 25686678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurocognitive function profile in HIV-infected school-age children.
    Koekkoek S; de Sonneville LM; Wolfs TF; Licht R; Geelen SP
    Eur J Paediatr Neurol; 2008 Jul; 12(4):290-7. PubMed ID: 17950012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.
    Tozzi V; Balestra P; Salvatori MF; Vlassi C; Liuzzi G; Giancola ML; Giulianelli M; Narciso P; Antinori A
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):56-63. PubMed ID: 19731418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.
    McDonald CR; Conroy AL; Gamble JL; Papp E; Hawkes M; Olwoch P; Natureeba P; Kamya M; Silverman M; Cohan D; Koss CA; Dorsey G; Kain KC; Serghides L
    Clin Infect Dis; 2018 Jan; 66(3):428-436. PubMed ID: 29136115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurocognitive and quality of life study in perinatally HIV-infected young people and their peers. NeuroCoRISpeS study.
    García-Navarro C; Martín-Bejarano M; Jimenez de Ory S; Zamora B; Ruiz-Saez B; Velo C; Cuéllar-Flores I; Garcia Lopez-Hortelano M; Guillen-Martin S; Navarro-Gómez ML; Ramos JT; González-Tomé MI;
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Nov; 38(9):417-424. PubMed ID: 32113706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurocognitive functioning of HIV positive children attending the comprehensive care clinic at Kenyatta national hospital: exploring neurocognitive deficits and psychosocial risk factors.
    Musindo O; Bangirana P; Kigamwa P; Okoth R; Kumar M
    AIDS Care; 2018 May; 30(5):618-622. PubMed ID: 29353495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.
    Resino S; Bellón JM; Ramos JT; Navarro ML; Martín-Fontelos P; Cabrero E; Muñoz-Fernández MA
    Pediatr Infect Dis J; 2004 Oct; 23(10):923-30. PubMed ID: 15602192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting.
    d'Arminio Monforte A; Gianotti N; Cozzi-Lepri A; Pinnetti C; Andreoni M; di Perri G; Galli M; Poli A; Costantini A; Orofino G; Maggiolo F; Mazzarello G; Celesia BM; Luciani F; Lazzarin A; Sighinolfi L; Rizzardini G; Bonfanti P; Perno CF; Antinori A;
    Antivir Ther; 2014; 19(3):319-24. PubMed ID: 24036891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detecting epilepsy-related cognitive problems in clinically referred children with epilepsy: is the WISC-IV a useful tool?
    Sherman EM; Brooks BL; Fay-McClymont TB; MacAllister WS
    Epilepsia; 2012 Jun; 53(6):1060-6. PubMed ID: 22554239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa.
    Meyers T; Sawry S; Wong JY; Moultrie H; Pinillos F; Fairlie L; van Zyl G
    Pediatr Infect Dis J; 2015 Feb; 34(2):175-9. PubMed ID: 25741970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
    Robertson K; Maruff P; Ross LL; Wohl D; Small CB; Edelstein H; Shaefer MS
    J Neurovirol; 2019 Feb; 25(1):22-31. PubMed ID: 30298202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.
    Tubiana R; Mandelbrot L; Le Chenadec J; Delmas S; Rouzioux C; Hirt D; Treluyer JM; Ekoukou D; Bui E; Chaix ML; Blanche S; Warszawski J;
    Clin Infect Dis; 2013 Sep; 57(6):891-902. PubMed ID: 23766338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.